REMARKS

The principal purpose of this Preliminary Amendment is to eliminate multiple dependencies in order to avoid extra fees.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

By: _____

Robert E. McCarthy (Reg. No. 46,044)
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201
Direct Dial: (703) 812-5322
Internet address: mccarthy@mwzb.com

Filed: February 4, 2002

VERSIONS WITH MARKING TO SHOW CHANGES MADE

3. (Amended) Use according to claim 1 ~~or 2~~, in which the radical that binds the endothelin receptor has the structure





Cys-Thr-Cys-Phe-Thr-Tyr-Lys-Asp-Lys-Glu-Cys-Val-Tyr-

Tyr-Cys-His-Leu-Asp-Ile-Ile-Trp,



Cys-Ser-Cys-Ser-Ser-Trp-Leu-Asp-Lys-Glu-Cys-Val-Tyr-

Phe-Cys-His-Leu-Asp-Ile-Ile-Trp,



Cys-Thr-Cys-Phe-Thr-Tyr-Lys-Asp-Lys-Glu-Cys-Val-Tyr-

Tyr-Cys-His-Leu-Asp-Ile-Ile-Trp,

Cys-Ser-Ala-Ser-Ser-Leu-Met-Asp-Lys-Glu-Ala-Val-Tyr-

Phe-Cys-His-Leu-Asp-Ile-Ile-Trp,



Cys-Ser-Cys-Asn-Ser-Trp-Leu-Asp-Lys-Glu-Cys-Val-Tyr-



Phe-Cys-His-Leu-Asp-Ile-Ile-Trp,



Cys-Ser-Cys-Lys-Asp-Met-Thr-Asp-Lys-Glu-Cys-Leu-Asn-



Phe-Cys-His-Gln-Asp-Val-Ile-Trp,



Ala-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-

Phe-Ala-His-Leu-Asp-Ile-Ile-Trp,

Ala-Ser-Ala-Ser-Ser-Leu-Met-Asp-Lys-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp,

Cys-Ser-Cys-Ser-Ser-Trp-Leu-Asp-Lys-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp,

Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp,

N-Acetyl-Leu-Met-Asp-Lys-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp,

His-Leu-Asp-Ile-Ile-Trp,

(DTrp)-Leu-Asp-Ile-Ile-Trp,

Cyclo-(DTrp-DAsp-Pro-DVal-Leu),

Cyclo-(DGlu-Ala-alloDIle-Leu-DTrp),

Cyclo(D-Trp-D-Asp-Pro-α-(2-thienyl)-D-Gly-Leu),

H-Gly-Asn-Trp-His-Gly-Thr-Ala-Pro-Asp-Trp-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-OH,



Cys-Thr-Cys-Asn-Asp-Met-Tyr-Ala-Glu-Glu-Cys-Leu-Asn-

Phe-Cys-His-Glu-Asp-Val-Ile-Trp,

Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp,

Ac-Leu-Met-Asp-Lys-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp,

Suc-Asp-Glu-Glu-Ala-Val-Thr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp,

Cys-Val-Tyr-Phe-Cys-His-Asp-Leu-Ile-Ile-Trp,



Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-

Phe-Cys-His-Leu-Asp-Ile-Ile-Trp,



Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-

Phe-Cys-His-Leu-Thr-γ-methyl-Leu-Ile-Trp

or is

a 4-t-butyl-N-[6-(2-hydroxy-ethoxy)-5-(3-methoxy-phenoxy)-4-pyrimidinyl-benzenesulfonamide radical,

a 4-t-butyl-N-[6-(1',2'-dihydroxy-propyloxy)-5'-(2-methoxy-phenoxy)-2-methoxy-4-pyrimidinyl-benzenesulfonamide radical,

a 4-t-butyl-N-[6'-(2'-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,2'-bipyrimidin-4-yl-benzenylsulfonamide radical,

a 27-O-caffeoylmyricerone radical, or

a 2(R)-[2-(R)-[2(S)-[[1-(hexahydro-1H-azepinyl)]-carbonyl]amino-4-methylpentanoyl]amino-3-[1-methyl-1H-indonyl)]propinonyl]amino-3-(2-pyridyl)propionic acid radical.

4. (Amended) Use according to claim 1 ~~or 2~~, in which the radical that binds the endothelin receptor has the structure

Leu-Asp-Ile-Ile-Trp,

Ac-His-Leu-Asp-Ile-Ile-Trp,

Ac-D-His-Leu-Asp-Ile-Ile-Trp,

Ile-Ile-Trp,

Asp-Gly-Gly-Cys-Gly-Cys-(D-Trp)-Leu-Asp-Ile-Ile-Trp,

Ac-D-Bhg-Leu-Asp-Ile-Ile-Trp, in which Bhg stands for a 10,11-dihydro-5 H-dibenzo-[a,d]-cycloheptenеglycine radical,

Ac-D-Bip-Leu-Asp-Ile-Ile-Trp, in which Bip stands for a 4,4'-biphenylalanine radical, or the structure

Asp-Gly-Gly-Cys-Gly-Cys-Phe-(D-Trp)-Leu-Asp-Ile-Ile-Trp.

5. (Amended) Use according to claim 1 ~~one of claims 1 to 4~~, in which the active group contains an alpha-, beta- and/or gamma-radiator, positron radiator, Auger electron radiator, x-ray radiator and/or a fluorescence radiator.

8. (Amended) Use according to claim 5 ~~one of claims 5 to 7~~, in which the radionuclide is ^{188}Re, ^{90}Y or ^{111}In.

11. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group contains a radionuclide of the elements At, Ba, Br, C, F, N, O or P.

12. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is vinblastine, doxorubicin, bleomycin, methotrexate, 5-fluorouracil, 6-thioguanine, cytarabine, cyclophosphamide or a cis-platinum radical.

13. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from a quercetin, genistein, erbstatin, lavendustin A, herbimycin A, aeroplysinin-1-tyrphostin-, S-aryl-benylidene malononitrile or benzylidene malononitrile radical.

14. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from a mercaptopurine, N-methyl-formamide, 2-amino-1,3,4-thiadiazole, melphalan, hexamethylmelanine, dichloromethotrexate, mitoguazone, sumarin, bromodeoxyuridine, iododeoxyuridine, semustine, 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea, N,N'-hexamethylene-bis-acetamide, azacytidine, dibromodulcitol, erwinia-asparaginase, ifosfamide, 2-mercaptoethanesulfonate, teniposide, taxol, 3-deazauridine, folic acid

antagonist, homoharringtonine, cyclocytidine, acivicin, ICRF-187, spiromustine, levamisole, chlorozotocin, aziridinylbenzoquinone, spirogermanium, aclarubicin, pentostatin, PALA, carboplatinum, amsacrine, caracemide, iproplatin, misonidazole, dihydro-5-azacytidine, 4'-deoxy-doxorubicin, menogaril, triciribine phosphate, fazarabine, tiazofurin, teroxirone, ethiofos, N-(2-hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide, mitoxantrone, acodazole, amonafide, fludarabine phosphate, pibenzimol, didemnin B, merbarone, dihydrolene perone, flavone-8-acetic acid, oxantrazole, ipomeanol, trimetrexate, deoxyspergualin, echinomycin or a dideoxycytidine radical.

15. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from an anti-PDGF or a triazolopyrimidine.

16. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from an RGD-peptide, which binds to GP IIb/IIIa receptors, from an acetylsalicylic acid, dipyridamole or thrombin radical.

17. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from heparin, hirudin, low molecular weight heparin or marcumar.

18. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from factor VIIa or Xa inhibitors.

19. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from a corticoid or a nonsteroidal anti-inflammatory agent.

20. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from colchicine, angiopeptin, estradiol or an ACE inhibitor.

21. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from verapamil, nifedipine or diltiazem.

22. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from simvastatin or probucol.

23. (Amended) Compound according to claim 9 ~~or 10~~, in which the active group is derived from an aptamer or antisense oligonucleotide.

24. (Amended) Therapeutic agents that contain a compound according to claim 9 ~~one of claims 9 to 23~~, dissolved, emulsified or suspended in an aqueous medium and the adjuvants, additives and/or stabilizers that are commonly used in galenicals.